As SCD1 inhibition may induce insulin sensitivity in muscle [100] and BAT [101], it is therefore plausible to explore the use of SCD as a potential therapeutic target for the treatment of insulin resistance and diabetes. The gene discussed is INS; the disease is diabetes mellitus.